Bioinformatics data analysis for next generation sequencing: RNASeq, DNASeq, ChIPSeq, and other NGS technologies across several therapeutic areas.
From West Virginia University - Sun, 07 Nov 2021 10:07:02 GMT - View all Morgantown, WV jobs

Funding Opportunity RFA-CA-21-061 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-21-NNN).

Notice NOT-CA-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-006 from the NIH Guide for Grants and Contracts

Notice NOT-DK-22-002 from the NIH Guide for Grants and Contracts

Notice NOT-EB-21-030 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: The European Bioinformatics Institute (EMBL-EBI) is seeking an enthusiastic Technical Team Lead for the European Genome-phenome Archive (EGA) located Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: In the frame of ARISE (Career Accelerator for Research Infrastructure Scientists) programme, we are looking for experienced professionals with a backg Germany (DE)

Competitive Salary: EMBL: In this role you will develop and manage the Ensembl Metazoa resource including our collaboration with VEuPathDB. As part of the Ensembl project, Ens Hinxton, Cambridgeshire, England

Funding Opportunity RFA-AG-22-026 from the NIH Guide for Grants and Contracts. The purpose of the Transition to Aging Research Award for Predoctoral Students is to increase, retain, and diversify the pool of trainees in aging and geriatric research.

Notice NOT-AG-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-062 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-001 from the NIH Guide for Grants and Contracts

Collaborate with R&D project teams, and manufacturing and QC teams to execute processes improvement plans. Process development as a member of product/process…
From Cellular Dynamics - Thu, 04 Nov 2021 05:38:43 GMT - View all Madison, WI jobs

Notice NOT-OD-22-017 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-056 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support a Research Resource for Human Organs and Tissues to provide continued availability of human tissues and organs to biomedical researchers. The research resource is expected to facilitate the procurement and preservation of human tissues and organs as well as the distribution of these materials to qualified biomedical researchers.

Funding Opportunity RFA-CA-22-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-22-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.